BIDZ, BIDZ.com, Inc.

** BIDZ reported that it has entered into a definitive merger agreement with Glendon Group, Inc. to be acquired for $0.78 per share in cash.

This per share price represents a premium of 59.2% over BIDZ’s closing price of $0.49 per share, on May 16, 2012, the last trading day prior to the execution of the merger agreement, and a premium of 37.7% over BIDZ’s volume-weighted average of the closing prices over the 30 consecutive trading days including and immediately preceding May 16, 2012.

BIDZ is a leading online retailer of jewelry. BIDZ offers its products through a live auction format as well as a fixed price online retail store, Buyz.com. BIDZ also operates Modnique.com, a division of Bidz.com, a flash sale shopping website, offering authentic premium brand name merchandise. Modnique offers its members exclusive access to 24-72 hour sales events on designer apparel, accessories, shoes, and housewares and much more at price points up to 85% below traditional retail prices.

More about BIDZ at www.bidz.com

***************

OSIR, Osiris Therapeutics, Inc.

** OSIR reported that it has received market authorization from Health Canada to market its stem cell therapy Prochymal(R) (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.

The historic decision marks the world’s first regulatory approval of a manufactured stem cell product and the first therapy approved for GvHD — a devastating complication of bone marrow transplantation that kills up to 80 percent of children affected, many within just weeks of diagnosis.

Prochymal was authorized under Health Canada’s Notice of Compliance with conditions (NOC/c) pathway, which provides access to therapeutic products that address unmet medical conditions and which have demonstrated a favorable risk/benefit profile in clinical trials. Under the NOC/c pathway, the sponsor must agree to carry out confirmatory clinical testing.

Health Canada’s authorization was made following the recommendation of an independent expert advisory panel, commissioned to evaluate Prochymal’s safety and efficacy. In Canada, Prochymal is now authorized for the management of acute GvHD in children who fail to respond to steroids.

Prochymal is currently available in several countries, including the United States, under an Expanded Access Program (EAP). Prochymal will be commercially available in Canada later this year.

In addition to the extensive intellectual property protection OSIR has around Prochymal, which includes 48 issued patents, Health Canada’s decision will also provide Prochymal with regulatory exclusivity within the territory. Canada affords eight years of exclusivity to Innovative Drugs such as Prochymal, and an additional six-month extension is available since it addresses a pediatric population.

GvHD represents a major unmet medical need with no approved treatment until Prochymal. GvHD is the leading cause of transplant related mortality, in which immune cells contained within the transplanted marrow recognize the recipient as foreign and mount an immunologic attack. Severe GvHD can cause blistering of the skin, intestinal hemorrhage and liver failure. Severe GvHD is extremely painful and fatal in up to 80 percent of cases. Currently, steroids are used as first-line therapy with a success rate of only 30-50 percent. When steroids fail, treatment options are limited to immunosuppressive agents used off-label with little benefit and significant toxicities.

Prochymal is the world’s first approved drug which has a stem cell as its active ingredient. Developed by OSIR, Prochymal is an intravenous formulation of mesenchymal stem cells (MSCs), which are derived from the bone marrow of healthy adult donors between the ages of 18 and 30 years.

OSIR is the leading stem cell company, having developed the world’s first approved stem cell drug, Prochymal. OSIR is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic areas and wound healing areas.

More about OSIR at www.Osiris.com

***************

MRCY, Mercury Computer Systems, Inc.

** MRCY reported that it has received a contract from a leading defense prime contractor to provide an advanced solid state data recorder for the aggregation and storage of sensor data from airborne ISR applications.

MRCY’s solution combines the very high density capacity Digital Storage Unit (DSU) with a controller function built to the 3U OpenVPX standard. The DSU uses an array of commercially available Solid State Disk (SSD) components configured within a compact, rugged, deployable enclosure, while the controller supports flexible protocol conversions as part of the data recording process.

MRCY is a best-of-breed provider of open, commercially developed, application-ready, multi-INT subsystems for defense prime contractors.

More about MRCY at www.mc.com

*****************

CRWE, Crown Equity Holdings Inc., CRWE.OB

Online video enables a totally new level of valuable communication among businesses – not only inside corporations themselves, but with respect to their client base.

CRWE recenly launched CRWE Tube, www.crwetube.com, a video sharing site that allows billions of people around the world to upload, watch and share original videos.

CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.

CRWE‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.

More about CRWE at www.crownequityholdings.com.

**********************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

 

 

Category: Stock Alerts

Tags: BIDZ, BIDZ.com, Crown Equity Holdings, CRWE, Mercury Computer, MRCY, Nasdaq:BIDZ, Nasdaq:MRCY, Nasdaq:OSIR, OSIR, Osiris Therapeutics, otc:crwe

GTAT, GT Advanced Technologies Inc.

** On its fourth quarter fiscal 2012, GTAT posted revenue $353.9 million, compared to $153.0 million in the third quarter of fiscal 2012 and $271.6 million in the fourth quarter of fiscal 2011; GTAT’s net income for the period was $79.1 million, compared to $15.3 million in the previous quarter and $51.9 million in the same period the prior year.

GTAT is a global provider of polysilicon production technology and sapphire and silicon crystalline growth systems and materials for the solar, LED and other specialty markets.

More about GTAT at www.gtat.com.

*****************

EGHT, 8×8 Inc.

** On its fourth quarter fiscal 2012, EGHT posted total revenue of $24.2 million, a 33% increase year over year, and GAAP net income of $63.9 million, or $0.87 per diluted share, compared with $2.0 million, or $0.03 per share in the same period the prior year (includes a one-time non-cash income tax benefit of $62.1 million associated with the release of a deferred tax asset valuation allowance in the fourth fiscal quarter).

EGHT is a leading provider of cloud communications and computing solutions.

More about EGHT at www.8×8.com

*****************

Internet is fast emerging as a popular medium of advertising because it is not limited by geography and time

Crown Equity Holdings Inc., (CRWE.OB) offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.

CRWE’s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.

CRWE’s division CRWE AD-Services (www.crwe-adservices.com), is a full service multimedia advertising company specializing in internet marketing. It provides modern and unique advertising campaigns, dedicated to offering the most cost effective advertising solutions.

More about CRWE at www.crownequityholdings.com.

*****************

CHMT, Chemtura Corporation

** CHMT reported that it has formed a long-term strategic agreement with Katoen Natie Group (KTN) to further strengthen CHMT’s proprietary Non-Dust Blend (Anox(R) NDB(R)) position in the marketplace.

This will combine CHMT’s proprietary technology with Katoen Natie’s centralized distribution location and world-class service. This project is part of CHMT’s antioxidant and UV stabilizer growth strategy, focused on becoming an even better and more competitive supplier.

In a parallel move, CHMT is combining its Anox(R) NDB(R) technology center with its global technical application center located in Trafford Park, Manchester, United Kingdom, to further strengthen CHMT’s ability to offer unique blending services that include feasibility studies, analytical evaluation of improved properties, and actual application performance data.

CHMT is a global manufacturer and marketer of specialty chemicals, agrochemicals and pool, spa and home care products.

More about CHMT at www.chemtura.com.

**********************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

 

 

Category: Stock Alerts

Tags: 8x8 Inc, Chemtura, CHMT, Crown Equity Holdings, CRWE, EGHT, GT Advanced, GTAT, Nasdaq:EGHT, Nasdaq:GTAT, NYSE:CHMT, otc:crwe

Highlights how Codexis platform enables breakthrough biocatalytic processes

REDWOOD CITY, Calif.–(CRWENewswire)–Codexis, Inc. (Nasdaq:CDXS), a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis’ patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.

The patent is titled “BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS” and was issued as U.S. patent number 8,178,333. The 20-year term of this patent does not expire until 2029.

“The patent is another example of how the Codexis CodeEvolver™ platform is enabling breakthrough biocatalytic processes to produce pharmaceutical intermediates, in this case for the latest hepatitis-C therapeutics,” said Peter Seufer-Wasserthal, Senior Vice President, Codexis Pharmaceuticals. “This patent specifically provides exclusivity for the use of our novel biocatalysts and production processes in the manufacture of these key intermediates. The ability to provide custom and high-performance manufacturing processes for our pharmaceuticals customers creates a competitive advantage for Codexis. ”

This patent follows a recently published article in the Journal of the American Chemical Society (JACS) that discusses collaborative research conducted by Merck and Codexis scientists to develop a highly efficient, enzyme-based production method for a key intermediate in the production of boceprevir.

To view the publication, please go to: http://pubs.acs.org/doi/pdf/10.1021/ja3010495

About Codexis, Inc.

Codexis, Inc. is a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates. Codexis’ product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see www.codexis.com.

Contact:

Codexis, Inc.
Investors: 212-362-1200
ir@codexis.com
Kelly McAlearney, 415-503-4073 (Media)
media@codexis.com

Source: Codexis, Inc.

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

 

 

Category: Press Releases

Tags: American Chemical Society, biocatalysts, biocatalytic, biocatalytic processes, Cellulase Enzymes, CodeEvolver, Codexis, CodeXyme, Detergent Alcohol, hepatitis C, Merck, NASDAQ:CDXS, Pfizer, US Patent and Trademark Office, USPTO

NEW YORK, May 15, 2012 (CRWENewswire)– Capital Trust, Inc. (NYSE:CT) (the “Company”) announced today that its Board of Directors (the “Board”) has formed a Special Committee of the Board comprised of independent directors (the “Special Committee”) to consider and explore strategic alternatives available to the Company in order to maximize shareholder value. The Special Committee intends to undertake a thorough exploration of the full range of alternatives, including a possible sale of the Company and has retained Evercore Partners to serve as its financial advisor.

No decision has been made to engage in a transaction or transactions resulting from the Special Committee’s exploration of strategic alternatives. There can be no assurance that that the Special Committee or the Board will authorize the pursuit of any strategic alternative. Moreover, there can be no assurance with respect to the terms or the timing of any transaction, or whether a transaction will ultimately result at all.

As a matter of policy, the Company does not comment on or provide the market with updates as to the status of any informal expressions of interest or formal proposals or offers presented to the Company from time to time, or the course of discussions with any prospective counterparties, nor will it comment upon any rumors with regard to either of the foregoing or make a further announcement regarding the Special Committee’s consideration of any proposal or other expressions of interest until such time, if ever, that it enters into a definitive agreement for a completed transaction or is otherwise required to make an announcement.

Forward-Looking Statements

This news release contains certain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements relating to future financial results and business prospects. The forward-looking statements contained in this news release are subject to certain risks and uncertainties including, but not limited to, the performance of the Company’s investments, the timing of collections, its capability to repay indebtedness as it comes due, competition for servicing and investment management assignments, its ability to originate investments, the availability of capital and the Company’s tax status, as well as other risks indicated from time to time in the Company’s Form 10-K and Form 10-Q filings with the Securities and Exchange Commission. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events or circumstances.

About Capital Trust

Capital Trust, Inc. is a fully integrated, self-managed real estate finance and investment management company that specializes in credit sensitive structured financial products. To date, the Company’s investment programs have focused primarily on loans and securities backed by commercial real estate assets, investing both for its balance sheet and for third party vehicles. Capital Trust is a real estate investment trust traded on the New York Stock Exchange under the symbol “CT.” The Company is headquartered in New York City.

Source: Capital Trust, Inc.

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

 

 

Category: Press Releases

Tags: board of directors, Capital Trust, Evercore Partners, investment management, NYSE:CT, real estate finance

CT, Capital Trust, Inc.

** CT reported that its Board of Directors has formed a Special Committee of the Board comprised of independent directors (the “Special Committee”) to consider and explore strategic alternatives available to CT in order to maximize shareholder value.

The Special Committee intends to undertake a thorough exploration of the full range of alternatives, including a possible sale of CT and has retained Evercore Partners to serve as its financial advisor.

No decision has been made to engage in a transaction or transactions resulting from the Special Committee’s exploration of strategic alternatives. There can be no assurance that that the Special Committee or the Board will authorize the pursuit of any strategic alternative. Moreover, there can be no assurance with respect to the terms or the timing of any transaction, or whether a transaction will ultimately result at all.

CT is a fully integrated, self-managed real estate finance and investment management company that specializes in credit sensitive structured financial products. To date, CT’s investment programs have focused primarily on loans and securities backed by commercial real estate assets, investing both for its balance sheet and for third party vehicles.

More about CT at www.capitaltrust.com

*****************

CDXS, Codexis, Inc.

** CDXS reported that the U.S Patent and Trademark Office (USPTO) has granted CDXS’ patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.

The patent is titled “BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS” and was issued as U.S. patent number 8,178,333. The 20-year term of this patent does not expire until 2029.

This patent follows a recently published article in the Journal of the American Chemical Society (JACS) that discusses collaborative research conducted by Merck and CDXS scientists to develop a highly efficient, enzyme-based production method for a key intermediate in the production of boceprevir (www.pubs.acs.org/doi/pdf/10.1021/ja3010495).

CDXS is a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates.

More about CDXS at www.codexis.com.

*****************

USHS, U.S. Home Systems Inc.

** For the first quarter 2012, USHS posted revenue of $42.2 million, an 8.3% increase year over year, and net income of $853,000, or diluted EPS of $0.11, compared to net income of $560,000, or diluted EPS of $0.08 in the same period the prior year.

USHS manufactures or procures, designs, sells and installs custom quality specialty home improvement products. USHS‘ product lines include kitchen cabinet refacing products utilized in kitchen remodeling, bathroom tub liners and wall surround products utilized in bathroom remodeling, and storage organization systems for closets and garages.

More about USHS at at www.ushomesystems.com.

**********************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

 

 

Category: Stock Alerts

Tags: Capital Trust, Codexis, NASDAQ:CDXS, Nasdaq:USHS, NYSE:CT, US Home Systems, USHS